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Tumour targeting using radiolabelled antibodies for radioimmuno-
detection (RID) and radioimmunotherapy (RIT) has been studied
for many years. The clinical success of antibody-directed cancer
treatment of common epithelial cancers has, however, been limited
by low tumour uptake, immunogenicity and poor therapeutic
ratios. In this paper we have used recombinant and chemical cross-
linking technologies to develop a series of novel fragments (King
et al, 1994, 1995; Antoniw et al, 1996; Casey et al, 1996), that
have shown improved biodistribution properties and potential for
future RID and RIT studies when compared to more conventional
antibodies. These fragments consist of divalent and trivalent Fab´
fragments referred to as DFM and TFM, which can be synthesized
from murine or humanized/chimaeric Fabs using mild conjugation
techniques. The chemical cross-linkers have been designed to
allow site-specific radiolabelling using 90Yttrium (90Y), a high
energy  b-emitter.
It is important to match the most suitable isotope to each engi-
neered antibody in order to achieve maximum therapeutic benefit.
131I has been the radionuclide used in the majority of RIT studies to
date because of its ready availability, low cost, simple conjugation
and effectiveness in responses in clinical RIT studies. However,
there are several limitations that have prompted the search for a
more suitable radiolabel. The high level of g-emission has led to
problems with patient handling, waste disposal and contributes to
myelosuppression. 90Y is a pure b-emitter with a comparatively
short half-life and thus 90Y-labelled antibodies may be an attractive
alternative.
Using the murine monoclonal anti-CEA antibody A5B7 and
its F(ab´)2 fragment radiolabelled with 131I, we have regularly
produced impressive growth regression and complete irradication
of tumours in nude mice bearing human colorectal tumour
xenografts (Pedley et al, 1993, 1996). However, clinical trials
using high doses of 131I-A5B7 (Lane et al, 1994), have produced a
response rate of only 10%, although this is in line with other
colorectal antibodies used for RIT and some of the best
chemotherapeutic agents such as 5-fluorouracil (5-FU). As a result
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we have been looking at various ways to improve the use of this
antibody in future RIT clinical trials.
A recent study was designed to compare different forms of the
murine antibody A5B7 raised against carcinoembryonic antigen
(CEA), in order to determine which was the optimal form of the
antibody for RIT with the isotopes 131I and 90Y (Casey et al, 1996).
Different forms of murine A5B7, namely DFM, F(ab´)2, IgG and
TFM were synthesized and the functional affinities for CEA were
measured under similar conditions using surface plasmon reso-
nance. The study revealed that there was a significantly faster
association rate for DFM compared to the other antibody forms.
TFM had the slowest dissociation rate; however, this was not
significantly different to the divalent antibody forms. This is prob-
ably a limitation of the analysis in measuring very slow dissocia-
tion rates, since other similar studies have shown clearly that TFM
forms of other antibodies show a significant advantage in terms of
a slower dissociation rate (King et al, 1994, 1995). These
improved kinetic binding characteristics of cross-linked DFM and
TFM may have implications for improved RIT. Biodistribution
experiments were also performed in this study to compare similar
sized F(ab´)2 and DFM, and IgG and TFM with both 131I and 90Y
(Casey et al, 1996). Results indicated the cross-linked antibodies
were highly stable in vivo and that 131I-DFM and 90Y-TFM would
be the most suitable combinations of antibody and radionuclide for
RIT with A5B7.
When selecting new possible candidates for RIT, it is important
to consider not only the biodistribution data at various time points
after injection, but also quantitative measurement of cumulative
radiation dose to tumour and normal tissues with respect to time.
Although these dosimetry calculations are based on data generated
from a murine model, and can be considered only as estimates,
they have previously proved to be useful predictors of toxicity and
a guide to the levels of activity that may be administered for RIT
(Pedley et al, 1989, 1993).
The results for this previous study were based only on func-
tional affinity and biodistribution data of both 131I and 90Y-labelled
F(ab´)2, DFM, IgG and TFM. In this second study, detailed
dosimetry analysis of the biodistribution data is described in
similar comparative experiments. These calculations were useful
in predicting the relative radiation doses that could be adminis-
tered for RIT, and an indication of the resulting toxicity.
MATERIALS AND METHODS
Preparation and characterization of DFM and TFM
Details of preparation and characterization of murine A5B7 DFM
and TFM have been described previously in detail by Casey et al
(1996). Briefly F(ab´)2 was partially reduced with 2-mercaptoethy-
lamine to form Fab´ fragments and produce a free hinge thiol for
cross-linking. After desalting to remove free reducing agent, a
2:1 molar excess of Fab´ to dimaleimide CT52 cross-linker and
a 3:1 molar excess of Fab´ to trimaleimide CT998 cross-linker was
added and the reaction left to proceed at 37°C for 2 h. Final purifi-
cation of DFM and TFM was performed by high-performance
liquid chromatography (HPLC) gel filtration.
Dosimetry
The estimated total doses of b-radiation (per MBq injected) to
the blood, tumour and normal tissues were evaluated for each
antibody-radiolabel conjugate using the following calculations.
Figures for percentage of injected activity per gram of each tissue
(% ia g–1) for individual mice were derived by direct measurement
Table 1 Biodistribution of 131I- and 90Y-labelled A5B7 F(ab´)2, DFM, IgG and TFM in mice bearing LS174T human tumour xenografts
131I-F(ab´)2
131I-DFM 90Y-F(ab´)2
90Y-DFM
3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h
Blood 13.3 0.25 0.09 0.01 10.4 0.30 0.12 0.02 10.1 0.41 0.30 0.19 7.24 0.19 0.29 0.15
Liver 4.63 0.15 0.05 0.01 3.26 0.15 0.06 0.01 5.10 7.75 3.12 0.64 11.1 8.25 6.30 0.92
Kidney 7.96 0.23 0.12 0.02 6.97 0.20 0.12 0.03 23.9 27.0 17.8 2.86 31.0 27.6 15.9 1.97
Lung 7.07 0.37 0.10 0.02 5.99 0.36 0.17 0.03 5.11 1.14 1.27 0.57 4.06 0.84 2.35 0.54
Spleen 4.56 0.25 0.10 0.03 4.16 0.30 0.10 0.09 4.84 8.37 4.77 1.94 9.73 11.2 11.4 3.77
Colon 2.20 0.10 0.04 0.02 1.67 0.13 0.07 0.04 1.54 1.46 1.36 0.32 1.83 1.70 1.45 0.34
Muscle 1.43 0.12 0.12 0.01 0.98 0.13 0.22 0.04 0.72 0.62 0.48 0.29 0.55 0.56 0.55 0.21
Femur – – – – – – – – 1.86 1.59 2.17 0.61 3.44 2.74 2.23 0.87
Tumour 9.67 9.15 3.72 1.50 10.6 7.40 4.41 1.03 9.32 9.19 6.38 0.91 6.66 6.81 6.62 1.25
131I-IgG 131I-TFM 90Y-IgG 90Y-TFM
3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h 3 h 24 h 48 h 144 h
Blood 33.5 9.81 3.32 0.46 24.2 2.71 0.64 0.06 19.7 5.28 3.09 0.36 19.1 1.08 0.33 0.04
Liver 9.25 3.88 0.74 0.23 6.50 0.93 0.38 0.07 6.10 7.63 8.71 2.83 12.1 7.02 5.29 0.97
Kidney 6.58 2.19 1.13 0.29 6.80 1.01 0.48 0.10 6.53 3.65 1.61 0.71 8.62 6.12 5.11 1.28
Lung 15.2 4.76 2.10 0.41 8.23 2.10 0.70 0.11 8.81 3.12 2.14 0.86 10.1 2.04 1.78 0.47
Spleen 9.10 3.03 0.79 0.36 7.12 1.13 0.61 0.18 5.65 4.32 2.90 1.99 8.20 8.19 5.83 1.28
Colon 2.08 1.11 0.47 0.23 2.02 0.63 0.39 0.13 2.17 1.59 0.88 0.58 2.18 2.04 1.19 0.42
Muscle 1.21 1.23 0.45 0.21 0.95 0.74 0.35 0.18 0.97 0.89 0.51 0.37 0.81 1.26 0.74 0.42
Femur – – – – – – – – 1.68 1.90 1.28 0.76 2.52 3.24 2.41 0.87
Tumour 8.73 19.6 14.5 6.25 11.2 15.1 8.80 2.38 8.28 23.0 16.6 4.43 7.32 16.8 10.8 1.75
Time points at 3 h, 24 h, 48 h and 144 h after intravenous injection. Results are expressed as percentage of injected activity per gram of tissue (median of four
mice per time point) and decay corrected using the decay constants for 131I and 90Y.974 JL Casey et al
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of blood and tissues using a g counter, and the average median
value was calculated for each time point as described in detail
in a previous publication (Casey et al, 1996). These values were
decay corrected using the following equation and figures shown
in Table 1.
A = A0 e–lt where l = Ln2/t1/2
t = time after injection
A0 = original activity at time t
A = activity at time t after decay correction
t1/2 = half-life of 194 h for 131I and 64 h for 90Y.
The area under the % ia g–1 over time curve (AUC) was calcu-
lated using the trapezoidal rule assuming no activity in the tumour
at time 0, and 40% in the blood at time 0. This value for blood was
generated from an experiment with both 131I-labelled A5B7 IgG
and F(ab´)2, in which blood samples were counted at 30 s post-
injection. An average of 39% IgG and 40.7% F(ab´)2 % ia g–1 was
present in the blood at this early time point. This is consistent with
the estimated total blood volume of a 20–30 g mouse being in the
range 2.0–2.5 ml as described by Durbin et al (1992). The total
decay corrected AUC was converted from % ia g–1 per mCi to
MBq g–1 using the following calculation: AUC per 100% ´ 1000
(for mCi) per 37 (for MBq).
To calculate total b dose to individual organs the MIRD S factor
of 0.369 for 131I and 1.93 for 90Y (MIRD Pamphlet 11, 1975) was
used to convert MBq g–1 to cGy h–1. This calculation does not
take into account the contribution of g energy as most of this
penetrating radiation escapes the mouse and there is virtually no
self-absorption of g rays. The calculation also assumes that there is
uniform distribution of activity, and there were no cross-organ
b radiation doses.
Total b doses to tumour and individual organs were normalized
to an equal dose of 100 cGy to the blood. This was achieved by
correcting the blood dose to 100 cGy then dividing or multiplying
the tissue doses by this correction factor. For example the blood
dose of 23 cGy for 131I-F(ab´)2 is multiplied by 4.35 to equal
100 cGy, the radiation doses to tumour and normal tissues are
multiplied by 4.35 to give the estimated absorbed dose at 100 cGy.
Radioimmunotherapy
To assess the therapeutic potential of DFM and TFM, RIT experi-
ments in the nude mouse xenograft model were designed. The
estimated dosimetry calculations were used to predict the total
activity of radiolabelled antibodies that should be administered for
RIT.
DFM and TFM were radiolabelled with 131I using the chloramine
T method. Free iodine was removed using a PD-10 coloumn, and
the percentage incorporation of radiolabel was analysed by thin-
layer chromatography (TLC) analysis in 80% methanol. Antigen
binding analysis was performed to ensure immunoreactivity was
retained, by applying a dilution of the radiolabelled antibody to a 1-
ml CEA affinity column and measuring the percentage bound, as
described previously by Casey et al (1995).
Therapy experiments were performed using the same nude
mouse model used for the biodistribution experiment described
previously (Casey et al, 1996). Experiments commenced when the
LS174T human colon carcinoma xenograft tumours were between
0.1–0.2 cm3 in volume and in exponential growth (7–10 days after
passaging). 18.5 MBq 131I-TFM and 37 MBq 131I-DFM were
injected intravenously via the tail vein into six mice per group, and
a further six untreated mice were used as a control group. Tumours
were measured and blood samples were taken (four mice per
group) from anaesthetized mice at regular intervals until the white
blood cell count (WBC) returned to normal and the tumour volume
reached 2 cm3, when mice were sacrificed. Four additional mice
per group were used for biodistribution, one-tenth of the dose for
RIT was administered and 24 h later blood, tumour and tissue
samples (liver, kidney, lung, spleen, colon, muscle, femur) were
removed for activity assessment in the g counter.
TFM and IgG were radiolabelled with 90Y using the method
described previously (Casey et al, 1996). Incorporation was
measured by TLC in 0.1 M citrate buffer pH 5.0, and HPLC gel
filtration was used to remove any free 90Y. For RIT 11.1 MBq
90Y-TFM and 5.6 MBq 90Y-IgG was injected into six mice per
group, six mice were left untreated as a control group. A further
four mice were used for a biodistribution experiment as for the
131I therapy. Tumour measurement and white cell blood counting
was also performed as described above.
Statistical comparisons were performed using the Mann–
Whitney  U-test for non-parametric statistical analysis.
RESULTS
The data illustrated in Table 1 was generated from comparative
biodistribution experiments of 131I- and 90Y-labelled A5B7 F(ab´)2
and DFM, and 131I- and 90Y-labelled A5B7 IgG and TFM, which
was described in detail previously (Casey et al, 1996). These
figures have been corrected for radioactive decay and were used to
calculate estimates of the total absorbed dose to blood, tumour and
Table 2 Estimated tissue doses of b-radiation (cGy) per MBq injected
activity calculated from the total area under the curve (AUC) using the
trapezoidal rule, from the biodistribution data presented in Table 1
Tissue 131I-F(ab´)2
131I-DFM 90Y-F(ab´)2
90Y-DFM
Blood 23.0 20.0 114 91.6
Liver 6.22 4.59 236 387
Kidney 10.8 9.73 1084 1065
Lung 10.0 9.19 99.2 122
Spleen 6.76 6.76 327 643
Colon 3.24 2.97 77.3 85.4
Muscle 2.70 2.97 34.1 32.7
Femur – – 113 145
Tumour 61.4 60.5 389 360
Tumour/blood ratio 2.67 3.03 3.41 3.93
Table 3 Estimated tissue doses of b-radiation (cGy) per MBq injected
activity calculated from the total area under the curve (AUC) using the
trapezoidal rule, from the biodistribution data described in Table 1
Tissue 131I-IgG 131I-TFM 90Y-IgG 90Y-TFM
Blood 90.3 44.9 322 175
Liver 25.1 12.4 470 349
Kidney 20.8 13.8 152 316
Lung 43.2 19.2 180 155
Spleen 24.1 15.4 227 360
Colon 8.65 6.77 74.3 85.4
Muscle 7.84 5.68 41.6 53.5
Femur – – 91.9 151
Tumour 172 111 951 627
Tumour/blood ratio 1.90 2.48 2.95 3.58Dosimetry and therapy of multivalent Fab´fragments 975
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normal tissues in the nude mouse LS174T human colorectal
tumour xenograft model.
Dosimetry
Total absorbed radiation doses were estimated by calculating the
AUC for each antibody-radiolabel conjugate and using the MIRD
correction factor to convert MBq to absorbed dose in cGy h–1.
These values are illustrated in Tables 2 and 3.
F(ab´)2 and DFM
The radiation doses and tumour to blood ratios were similar for
F(ab´)2 and DFM when each was labelled with the same isotope
(Table 2). However, there was a wide discrepancy between the two
radionuclides 131I and 90Y; tissue doses per MBq administered from
90Y-labelled antibody fragments were at least tenfold higher than
those delivered by 131I-labelled antibody fragments.
A notable difference between the radionuclides is the high dose
to the kidney on radiolabelling with 90Y (1065–1084 cGy), which
is 100 times greater than for 131I-labelled F(ab´)2 and DFM
(9.73–10.8 cGy). In spite of its size, it is evident that a large
proportion of antibody clears through and is retained by the kidney
and the toxicity to this organ would severely limit the dose of 90Y
that could be administered for therapy.
The dosimetry calculations also revealed higher absorbed doses
for spleen (DFM: 643 cGy, F(ab´)2: 327 cGy) and liver (DFM:
387 cGy, F(ab´)2: 236 cGy) on administration of 90Y-DFM
compared to 90Y-F(ab´)2. There may be higher non-specific uptake
of  90Y-DFM by the RES that could account for the increase in
overall dose to these organs.
IgG and TFM
As found for the F(ab´)2 and DFM, the radiation dose delivered to
all tissues per MBq 90Y-labelled antibodies was far greater than
from the 131I-labelled antibodies. Radiation doses to blood, tumour
and all normal organs were lower on administration of 131I-TFM
compared to 131I-IgG (Table 3). This reflects the faster clearance of
TFM from the circulation and normal tissues due to the lack of the
Fc portion, which is responsible for the long half-life of IgG
through FcRn-mediated recycling (Ghetie et al, 1997). However,
this was not observed with 90Y-TFM; although blood and tumour
levels were lower, doses to normal tissues were similar and some-
times greater than for 90Y-IgG. This is most likely due to retention
of 90Y in cells for longer than 131I, as has been demonstrated previ-
ously (Press et al, 1996), which contributes largely to the toxicity.
The faster blood clearance of TFM compared to IgG is reflected
here in the overall blood doses and tumour to blood ratios
(Table 3). The bone marrow has been identified as the dose-
limiting organ in RIT. The clearance rate of radioactivity from the
blood has been suggested as a means of predicting bone marrow
toxicity (Siegal et al, 1990), because dose to the marrow equals
0.2–0.4 times that of the blood. Therefore since the blood received
approximately half the cumulative dose on administration of
131I-TFM or 90Y-TFM compared to IgG conjugates, this will result
in a favourable twofold decrease in toxicity to the bone marrow.
Normal tissue toxicity for both iodine labelled IgG and TFM
was low and the largest normal tissue dose excluding blood (bone
marrow) was to the lungs. Histological studies have demonstrated
that A5B7 IgG shows some cross-reactivity with lung tissue
(Boxer et al., 1995), which is possibly due to the presence of low
normal levels of CEA produced in the lungs.
The largest normal tissue doses for 90Y-IgG were to the liver and
spleen and for 90Y-TFM the liver, kidney and spleen. The absorbed
dose to the kidney was doubled for 90Y-TFM compared to 90Y-IgG,
but was fourfold lower than for the smaller 90Y-labelled fragments.
It is likely that a proportion of 90Y-TFM or fragments of 90Y-TFM
are filtered by the kidney and cleared via this route, which may
explain this increase in dose. Conversely, the liver dose for
90Y-TFM was lower than for 90Y-IgG which clears largely via the
liver. A higher spleen dose was generated on administration of
90Y-TFM compared to 90Y-IgG, and this may be due to increased
recognition by the RES. Absorbed dose to the bone was also
higher for 90Y-TFM but this level was similar to the absorbed dose
by other normal organs such as lung.
Comparative dosimetry of antibodies after blood
normalization
Radiation dose estimates provided in Table 2 and 3 were normal-
ized to an equal dose (100 cGy) to the blood in Table 4. Since the
levels of radioactivity in the blood has been suggested as a means
of predicting bone marrow toxicity (Siegel et al, 1990) this Table,
based on an equal blood dose, should reflect the estimated tumour
dose and normal tissue toxicity at approximately equal myelotoxic
levels.
Table 4 Radiation dose estimates to organs in nude mice given 131I- or 90Y-labelled A5B7 F(ab´)2, DFM, IgG or TFM (Tables 2 and 3)
normalized to a 100 cGy blood dose
131I 131I 131I 131I 90Y 90Y 90Y 90Y
Tissue F(ab´)2 DFM IgG TFM F(ab´)2 DFM IgG TFM
Blood 100 100 100 100 100 100 100 100
Liver 27.0 23.0 27.8 27.6 207 422 146 199
Kidney 47.0 48.7 23.0 30.7 951 1163 47.2 181
Lung 43.5 46.0 47.8 42.8 87.0 133 55.9 88.6
Spleen 29.4 33.8 26.7 34.3 287 702 70.5 206
Colon 14.1 14.9 9.60 15.1 67.8 93.2 23.1 48.8
Muscle 11.7 14.9 8.68 12.7 29.9 35.7 12.9 30.6
Tumour 267 303 191 247 341 393 295 358
TEDNT 173 181 144 163 1630 2549 356 754
Ratio 1.54 1.67 1.33 1.52 0.21 0.15 0.83 0.47
TEDNT refers to total estimated dose to normal tissues which is the sum of the dose estimates for liver, kidney, lung, spleen, colon and
muscle. NB. Femur has not been included. Ratio refers to tumour to normal tissue (TEDNT) ratio.976 JL Casey et al
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90Y-labelled antibodies
Referring to the total estimated toxicity doses to normal tissues
(TEDNT) in Table 4, clearly the extremely high levels for
90Y-F(ab´)2 and 90Y-DFM should exclude these combinations from
further consideration for RIT. This limits the choice to either IgG
or TFM labelled with 90Y, both of which are worthy of further
consideration. For equitoxic levels to the blood a slightly higher
tumour dose was estimated for 90Y-TFM, but the dose to normal
tissues was 2.1 times higher than that of 90Y-IgG. TEDNT for
90Y-TFM was 2.1 times greater than the estimated dose to the
tumour, whereas TEDNT was only 1.2 times greater than the
tumour dose for 90Y-IgG. This suggests that for a given blood
dose 90Y-IgG would be less toxic than 90Y-TFM. Thus a higher
therapeutic tumour:normal tissue ratio was achieved for IgG,
suggesting that RIT with the isotope 90Y would be least toxic by
conjugation to IgG, allowing increased doses of isotope which
may lead to more effective therapy.
131I-labelled antibodies
All combinations of antibodies labelled with 131I corrected for
equitoxic blood levels produced similar TEDNT (range 144–
281 cGy) and tumour doses (range 191–303 cGy). The highest
tumour:normal tissue ratios were achieved for the smaller sized
fragments DFM and F(ab´)2 suggesting favourable therapeutic
advantage over TFM and IgG. The highest tumour dose and
tumour:normal tissue ratio overall was for DFM, implying that
RIT with the isotope 131I would be most effective by conjugation
to DFM.
Radioimmunotherapy
RIT of 131I labelled DFM and TFM
The dosimetry calculations revealed that for the same administered
activity (MBq), the blood and tumour dose of 131I-TFM was
approximately double that of 131I-DFM. It was therefore estimated
that similar therapy and toxicity would be achieved by adminis-
tering twice the amount of activity of 131I-DFM compared to
131I-TFM. The amount of activity to be administered for RIT
studies was calculated with reference to therapeutic levels admin-
istered in previous RIT studies with A5B7 131I-IgG and 131I-F(ab´)2.
RIT experiments demonstrated identical therapeutic response by
administration of 18.5 MBq 131I-IgG and 37 MBq F(ab´)2 (Pedley
et al, 1993).
DFM was labelled with 131I to a specific activity of 0.37 MBq
mg–1 and TFM to 0.26 MBq mg–1. TLC after desalting revealed
90% incorporation of 131I for TFM and 95% incorporation for
DFM. Antigen binding analysis post-labelling resulted in retention
of 75% binding of 131I-TFM and 86% of 131I-DFM. For RIT
18.5 MBq  131I-TFM and 37 MBq 131I-DFM was injected into six
mice per group. Biodistribution at 24 h in Figure 1 demonstrated
efficient tumour localization of both DFM and TFM.
Figure 2 shows the mean tumour growth following administra-
tion of therapeutic levels of 131I-DFM and 131I-TFM compared to a
no treatment control group. Both DFM and TFM produced a
significant therapeutic effect when compared with the control
group (P < 0.05). Tumour growth was delayed for approximately
25 days for both conjugates, and there was no significant differ-
ence between the two therapy groups (P > 0.05).
Toxicity was assessed by measurement of white blood cell count
(WBC) at weekly intervals until the WBC returned to normal
levels (Figure 3). Little toxicity was produced by either DFM or
TFM (P > 0.05) and for 2/4 mice from each group the WBC was
unaffected after treatment. The remaining 2/4 mice treated with
131I-DFM and 131I-TFM showed similar toxicity, with a maximum
fall in WBC of > 30% up to 14 days post-therapy. After 21 days
the WBC returned to normal for both TFM and DFM (i.e. equiva-
lent or greater than the original pre-therapy figure). Control
mice also experienced a decrease in WBC when tumours were
approaching 2 cm3.
RIT of 90Y labelled IgG and TFM
The blood radiation dose was doubled on administration of the
same activity (MBq) of 90Y-IgG compared to 90Y-TFM. Assuming
the same principle that toxicity is related to total blood dose which
in turn reflects absorbed marrow dose, it was predicted that twice
the amount of activity of TFM compared to IgG could be adminis-
tered for the same level of toxicity. An RIT study was designed
with reference to dosimetry evaluations and previous therapeutic
levels of activity administered for 90Y-IgG of another antibody
A33 (Antoniw et al, 1996).
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Figure 1 Biodistribution of one-tenth of the administered activity for therapy
of 131I-DFM and 131I-TFM 24 h after injection to nude mice bearing LS174T
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Figure 2 Effect of treatment regimes on the growth of LS174T tumours with
(A) 131I-DFM, (B) 131I-TFM and (C) no treatment control group. Vertical bars
indicate standard error of the mean (s.e.m.); points are a mean of six miceDosimetry and therapy of multivalent Fab´fragments 977
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Figure 3 White blood cell counts (WBC) measured weekly from four mice
per group. Results are expressed as a % of the original pre-therapy WBC,
for individual mice
30
20
10
0
IgG
TFM
Blood Liver Kidney Lung Spleen Colon Muscle Femur Tumour
Tissues
%
I
n
j
e
c
t
e
d
 
a
c
t
i
v
i
t
y
/
g
Figure 4 Biodistribution of one-tenth of the dose administered for therapy of
90Y-IgG and 90Y-TFM 24 h after injection to nude mice bearing LS174T human
tumour xenografts. Results are expressed as % of injected activity per gram
of tissue, columns are a mean of four mice and bars represent standard
deviations
3
2
1
0
0 1 02 03 04 05 0 6 0
Time (days)
IgG
TFM
Control
T
u
m
o
u
r
 
s
i
z
e
 
c
m
3
Figure 5 Effect of treatment regimes on the growth of LS174T tumours with
(A) 90Y-IgG, (B) 90Y-TFM and (C) no treatment control group. Vertical bars
indicate s.e.m., points are a mean of six mice
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Figure 6 White blood cell counts (WBC) measured weekly from four mice
per group. Results are expressed as a % of the original pre-therapy WBC978 JL Casey et al
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IgG was labelled to a specific activity of 0.09 MBq mg–1 and
TFM to 0.15 MBq mg–1. Free 90Y was removed by HPLC purifica-
tion as described previously (Casey et al, 1996), and TLC analysis
showed > 90% incorporation of radiolabel. Antigen binding
analysis post-labelling resulted in 71% binding of IgG and 86% for
TFM. Biodistribution at 24 h in Figure 4 demonstrated efficient
tumour localization of both IgG and TFM.
Figure 5 illustrates the relative growth delay of 90Y-IgG and
90Y-TFM compared to a no treatment control group. Both IgG and
TFM produced a significant therapeutic effect when compared
with the control group (P < 0.05). Tumour growth was delayed for
approximately 17 days for TFM and 31 days for IgG. The thera-
peutic response of 90Y-TFM was not as effective as 90Y-IgG despite
administration of double the amount of activity.
Toxicity, assessed by WBC (Figure 6), was observed for all
mice except the control group and lasted up to 21 days. Although
predicted to be equal by dosimetry estimates, the overall toxicity
was greatest for IgG, resulting in a fall of WBC in all four mice at
14 days to 40% (range 5–40%) of the pre-therapy WBC. For TFM
the greatest fall in WBC was observed 7 days post-injection to
30% (range 20–30%). By 14 days recovery of WBC resulted in a
return to 70% (range 28–70%) of the original value. At 21 days
post-injection there was almost complete recovery of WBC, with
the exception of 2/4 mice treated with 90Y-TFM, which had WBC
of 56% and 64% of the original values. This slower return to
normal WBC levels is most likely due to the higher dose adminis-
tered, but there was no significant difference in WBC toxicity
between IgG and TFM levels at each time point (P > 0.05).
DISCUSSION
Chemically cross-linked divalent and trivalent versions of the
murine antibody A5B7 have shown high stability both in vitro and
in nude mice bearing human tumour xenografts (Casey et al,
1996). In this previous study the cross-linked antibodies showed
potential as possible new candidates for RIT, with favourable
affinity, biodistribution and tumour uptake coupled with the ability
to humanize for reduced immunogenicity. The aim of this study
was to measure quantitatively the dose to tumour and normal
tissue and to use these estimates to predict the relative doses for
use in therapeutic studies. To date only a few studies have con-
sidered measurement of radioactivity dose to tissues in model
systems, and it is becoming clear that this preclinical data is very
important in assessing the level of toxicity to normal tissues
compared to the dose to tumour. This is particularly pertinent
when the aim is to select optimal combinations of radionuclide and
antibody for RIT.
The most prominent difference between the two radionuclides
was the increase in dose to all tissues on labelling with 90Y
(Tables 2 and 3). Blood doses were 4–6 times higher for divalent
antibodies labelled with 90Y as opposed to 131I, and 3–4 times
higher for TFM and IgG. Similarly tumour levels were five- to
sixfold higher than for an equivalent injected dose of 131I-labelled
antibodies. Several other publications (Sharkey et al, 1990; Schott
et al, 1992; King et al, 1994) have also reported similar increases
in blood and normal tissue levels and tumour retention for
90Y-labelled antibodies. This resulted in all tumour to blood
ratios for 90Y-labelled antibodies being slightly higher than for
131I-labelled antibodies.
However, when radiation doses estimates were corrected for
equitoxic levels to the blood (Table 4), and the tumour to normal
tissues ratios of radiation dose were considered, the ratios for all
90Y-labelled antibodies were lower than those for 131I-labelled anti-
bodies. This is an interesting finding, as the biodistribution and
dosimetry results had previously favoured use of 90Y-labelled
antibodies based on the higher tumour to blood ratios. For RIT,
efficient tumour localization is required to achieve high levels of
tumour cell kill, but the corresponding dose to normal tissues is
also a major consideration. Since the absorbed dose to normal
tissues contributes to overall myelotoxicity, this finding suggests
that the maximum tolerated dose in RIT studies will be lower
for 90Y-labelled antibodies than for those labelled with 131I. The
therapeutic effects of 131I-labelled antibodies were not directly
compared here. But in two similar studies it was concluded that,
despite the efficacious energy emissions of 90Y, IgG labelled with
131I may have equal or better therapeutic prospects than 90Y-IgG as
a consequence of the higher retention of 90Y-IgG in normal organs
(Buchsbaum et al, 1990; Sharkey et al, 1990).
It is unlikely that the higher radiation dose to the normal tissues
after radiolabelling with 90Y is a product of conjugate instability. It
is well known that free 90Y accumulates in the bone (Harrison et al,
1991), but the cumulative dose to the bone throughout this study
was relatively low and not vastly different to that of other normal
tissues, thus reflecting the high stability of the macrocycle
conjugate. It is also unlikely that the higher radiation doses of
90Y-labelled antibodies were due to different distribution of the
antibody. The same preparations of antibody fragments were used
in each experiment and after radiolabelling immunoreactivity and
original size characteristics were retained (Casey et al, 1996).
Therefore the increase in tissue doses of 90Y-labelled antibodies is
most probably due to the higher energy of and greater path length
of the pure b-emitter 90Y, while 90Y is also known to be retained
within cells for longer than 131I (Press et al, 1996).
The major organs contributing to the increase in absorbed dose of
90Y-labelled antibodies were the kidney, liver and spleen. The high
kidney uptake level for 90Y-labelled F(ab´)2 and DFM was first
recognized in the previous biodistribution study (Casey et al, 1996),
and here the absorbed dose to the kidney for 90Y-labelled F(ab´)2 and
DFM was increased by approximately 100-fold compared to their
respective  131I-labelled fragments. Conventional radiotherapy
studies have indicated that doses to this organ should not exceed
1500 cGy (Fawwaz et al, 1986), therefore cumulative kidney doses
of 1065 or 1084 cGy MBq–1 b-radiation for both 90Y-DFM and
90Y-F(ab´)2 respectively are clearly unacceptable for RIT.
In contrast to the divalent fragments, kidney accumulation of
90Y-TFM was greatly reduced. This is presumably mainly due to
the increase in molecular weight, which theoretically restricts
passage through the glomerular filter; however, there may be other
factors such as shape and charge which also influence the filtration
process (Sumpio and Hayslett, 1985). Nevertheless, estimated
total absorbed dose to the kidney was approximately doubled on
administration of 90Y-TFM (316 cGy MBq–1) compared to 90Y-IgG
(152 cGy MBq–1), but the absorbed dose for respective
131I-labelled antibodies was fairly similar: 13.8 cGy MBq–1 and
20.8 cGy MBq–1. The difference is likely to be concerned with
the processing of catabolic products rather than de-iodination.
Radiometals such as 90Y are trapped within lysosomes whereas
iodine is more readily released from cells as monoiodotyrosine
(Press et al, 1996). It is also feasible that the higher stability of the
thioether bond may slow down catabolism in the kidney tubules,
and this effect was higher for 90Y-TFM due to the retention of this
radionuclide within the cells.Dosimetry and therapy of multivalent Fab´fragments 979
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High kidney uptake of radiolabelled antibody fragments has
been described in several other biodistribution studies, and this
effect is more apparent with intracellularly retained radionuclides
than with iodine (Sharkey et al, 1990; Behr et al, 1995; Kobayashi
et al, 1996). Current research is being directed into ways of
enhancing renal excretion of radiolabelled antibody fragments.
One approach is based on blocking kidney tubules with cationic
amino acids in order to block anionic sites and inhibit tubular reab-
sorption of radiolabelled fragments. A fivefold reduction in kidney
uptake for 99mTc-Fab fragments (Behr et al, 1995) and similarly a
fivefold reduction for 177Lu-Fab (DePalatis et al, 1995) has been
demonstrated using this approach. Other strategies include modifi-
cation of the charge of antibody fragments to reduce the pI in
attempt to prolong the serum half-life by retarding molecular
sieving (Tarburton et al, 1990) or direct uptake by the kidney
tubular cells without glomerular filtration. In a recent study by
Kobayashi et al (1999) renal accumulation of Fab´ fragments
increased significantly as the pI increased (pI 7–9.3). A5B7
F(ab´)2 and DFM both have a pI of 8, therefore reduction of the pI
using techniques such as glycolation could significantly reduce the
renal uptake of these fragments.
Liver and splenic uptake levels of 90Y-labelled antibodies were
also elevated. In Tables 2 and 3, an 18- to 80-fold increase in
liver and 10- to 95-fold increase in splenic activity compared to
131I-labelled antibodies was observed. Both the liver and spleen are
organs of the reticuloendothelial system and are involved in the
clearance of antibody complexes from the circulation. Therefore it
was not surprising that there was a higher absorbed dose to these
organs, especially for 90Y-labelled antibodies due to longer intra-
cellular retention of the radiolabel. Both the liver and spleen are
relatively radioresistant organs when compared to the kidney,
being able to tolerate much higher doses of radiation before there
is a possibility of permanent toxicity damage. However, the contri-
bution to overall myelotoxicity should not be disregarded.
Considering all the combinations of antibody and radionuclide
corrected for equitoxic blood levels, the highest tumour to normal
tissue ratio of absorbed dose was achieved for 131I-DFM,
suggesting that this would be the optimal combination for RIT.
Because other ratios for 131I-labelled antibodies were only slightly
lower than for 131I-DFM, it was decided to select 131I-TFM for
comparative therapy experiments. The dosimetry estimates
were in agreement with RIT results in that twice the activity of
131I-DFM must be administered in order to produce the same
therapeutic effect as 131I-TFM. This is because the more rapid
circulatory clearance of DFM compared to the higher molecular
weight TFM results in lower tumour levels for the same injected
activity. However, the advantage of this is that the increased
tumour to blood ratio produced by DFM enables administration of
larger amounts of radioantibody before a similar level of toxicity
to the bone marrow is reached. Also, administration of twice the
activity of DFM will result in a higher initial dose rate to the
tumour, which produces the same inhibition of tumour growth as
TFM, although the latter is retained in the tumour for longer.
Toxicity measured by WBC in this study was minimal, implying
that larger doses of both 131I-DFM and 131I-TFM may be adminis-
tered to produce longer tumour regression or complete cures.
Despite the improved tumour:blood ratios for TFM, the
increased estimated dose to normal tissues suggested that the most
promising combination with the radionuclide 90Y appeared to be
IgG. This is contrary to the conclusion reached in the previous
publication that 90Y-TFM is optimal, based simply on the
improved tumour to blood ratios for the biodistribution experiment
(Casey et al, 1996). This confirms the importance of comparing
radiation dose ratios for tumour and normal tissues as well as those
for blood. After correction for equitoxic blood levels, dosimetry
revealed that doses to normal tissues were in fact twice the level of
IgG, producing a twofold increase in the overall tumour to normal
tissue ratio. This indicates that 90Y-IgG is a more suitable alterna-
tive to 90Y-TFM. 90Y-TFM administered at twice the activity of
90Y-IgG produced slightly less WBC toxicity, but also a lower
therapeutic response. This indicates that higher levels of adminis-
tered activity of 90Y-TFM are required to produce a similar growth
delay to 90Y-IgG, but will most likely produce higher toxicity as
predicted by the dosimetry calculations. Ultimately the higher
residence time of 90Y-TFM in normal tissues had a negative effect
by increasing toxicity, thus reducing the total dose that may be
safely administered therapeutically.
There are certain advantages of antibody fragments that should
not be disregarded when selecting the most appropriate targeting
entity. The Fc portion of the antibody is effectively redundant in
terms of antibody binding of a carrier molecule and is also the
most immunogenic part of an antibody. Thus removal of the Fc
does not generally compromise immunoreactivity but does reduce
overall immunogenicity. Antibody fragments are also known to be
advantageous in terms of increased speed of tumour penetration,
which can result in delivery of a dose that is more evenly distrib-
uted throughout the tumour mass (Yokota et al, 1992). Tumour
penetration was not compared in this study, but a similar recent
report by Antoniw et al (1996) demonstrated more rapid penetra-
tion of A33 TFM compared to A33 IgG.
Recent studies have focused on measurements of the micro-
distribution of radiolabelled antibodies within tumours. Using
phosphor plate technology (Johnson et al, 1990), a three-
dimensional tumour dosimetry model has been designed to
measure microscopic dose measurements to study the distribution
of radiolabelled antibodies and fragments within tumours over
time (Flynn et al, 1998). A potential application of this and other
similar models is to study the importance of binding affinity in
areas of low or high antigen density within tumours. Initial experi-
ments comparing the biodistribution of radiolabelled DFM and
F(ab´)2 within tumour sections (xenografts) have implied that
DFM was retained in viable areas of the tumour for longer than
F(ab´)2, which was more evenly distributed throughout cellular
and necrotic regions. This could be explained by the increase in
functional affinity of DFM and may have implications for
improved RIT.
In the previous study DFM and TFM also demonstrated faster
on-rates and slower off-rates than F(ab´)2 and IgG (Casey et al,
1996). Since human tumours are known to have a more hetero-
geneous distribution of antigen compared to most human
xenograft tumours, higher affinity may be advantageous in terms
of improved binding to areas of low antigen density (Sung et al,
1992). Future microdosimetric analysis may reveal the true poten-
tial of improved on and off-rates for DFM and TFM in human
tumours, which may further assist in selection of antibody and
radionuclide for future clinical trials.
The results described here on the basis of the highest tumour to
normal tissue dose ratio at equitoxic blood levels, suggests that
DFM labelled with 131I is the best combination of antibody and
radionuclide for future RIT. This is consistent with the conclusions
in the previous publication which indicated that DFM radio-
labelled with 131I would be optimal, due to a significantly faster980 JL Casey et al
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on-rate than for all other antibody forms (Casey et al, 1996).
However since RIT studies showed that 131I-TFM produced a
similar therapeutic response to 131I-DFM, this combination should
not be disregarded. Further RIT dose escalation studies and
toxicity assessment are required to select the best combination
for future RIT with 131I.
Future RIT experiments should involve comparisons of
131I-DFM and 90Y-IgG, including toxicity measurements, together
with microdosimetric analysis in order to select the optimal combi-
nation of antibody and radionuclide for A5B7.
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